carbamazepine and As If Personality studies

Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.
carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.

Research Excerpts

Excerpt	Relevance	Reference
"Sixteen female outpatients with borderline personality disorder and prominent behavioral dyscontrol, but without a current episode of major depression, were studied in a double-blind, crossover trial of placebo and the following four active medications: alprazolam (average dose, 4."	9.06	Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. ( Cowdry, RW; Gardner, DL, 1988)
"In a double-blind crossover trial, carbamazepine, an anticonvulsant with primary effects on subcortical limbic structures, decreased the severity of behavioral dyscontrol in 11 women with borderline personality disorder significantly more than placebo."	9.06	Positive effects of carbamazepine on behavioral dyscontrol in borderline personality disorder. ( Cowdry, RW; Gardner, DL, 1986)
"Because patients with borderline personality disorder show prominent affective symptomatology on the one hand and symptoms suggestive of an epileptoid disorder on the other, carbamazepine was included in a multidrug, placebo-controlled, double-blind study."	6.66	Development of melancholia during carbamazepine treatment in borderline personality disorder. ( Cowdry, RW; Gardner, DL, 1986)
"Sixteen female outpatients with borderline personality disorder and prominent behavioral dyscontrol, but without a current episode of major depression, were studied in a double-blind, crossover trial of placebo and the following four active medications: alprazolam (average dose, 4."	5.06	Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. ( Cowdry, RW; Gardner, DL, 1988)
"In a double-blind crossover trial, carbamazepine, an anticonvulsant with primary effects on subcortical limbic structures, decreased the severity of behavioral dyscontrol in 11 women with borderline personality disorder significantly more than placebo."	5.06	Positive effects of carbamazepine on behavioral dyscontrol in borderline personality disorder. ( Cowdry, RW; Gardner, DL, 1986)
" The anticonvulsants valproate and topiramate appeared to have the most empirical support for having a favorable effect on symptoms of borderline personality disorder."	4.85	[Empirical evidence for the use of anticonvulsants in personality disorders]. ( Emrich, HM; Sieberer, M, 2009)
"Because patients with borderline personality disorder show prominent affective symptomatology on the one hand and symptoms suggestive of an epileptoid disorder on the other, carbamazepine was included in a multidrug, placebo-controlled, double-blind study."	2.66	Development of melancholia during carbamazepine treatment in borderline personality disorder. ( Cowdry, RW; Gardner, DL, 1986)
"The literature on the pharmacotherapy of Borderline Personality Disorder (BPD) is critically reviewed, and suggestions for the appropriate clinical use of psychotropic agents and directions for future research are made."	2.38	Pharmacotherapy of the borderline patient: a critical review and clinical guidelines. ( Blackwood, DH; Kutcher, SP, 1989)
"Early treatment of epilepsy is warranted to avoid possible severe consequences."	1.39	Epilepsy and brain injury: a case report of a dramatic neuropsychiatric vicious circle. ( Angeletti, G; Carbonetti, P; Del Casale, A; Fensore, C; Ferracuti, S; Girardi, P; Kotzalidis, GD; Lazanio, S; Muzi, A; Rapinesi, C; Savoja, V; Scatena, P; Serata, D; Tatarelli, R, 2013)
"Carbamazepine (100 mg/day) was added in expectation of further improvement."	1.31	[Successful treatment using low-dose carbamazepine for a patient of personality change after mild diffuse brain injury]. ( Iida, J; Kishimoto, T; Matsumoto, H; Morikawa, M; Tatsuda, H; Tokuyama, A, 2000)
"Carbamazepine was well tolerated."	1.26	[Evaluation of different treatment in minimal brain damage]. ( Castañón de Martínez, V; Ortiz de Alemán, MY, 1977)

Research

Studies (26)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Clinicians Global Impression of Change

Timeframe	Studies, this research(%)	All Research%
pre-1990	12 (46.15)	18.7374
1990's	8 (30.77)	18.2507
2000's	4 (15.38)	29.6817
2010's	2 (7.69)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Rapinesi, C	1
Del Casale, A	1
Serata, D	1
Kotzalidis, GD	1
Scatena, P	1
Muzi, A	1
Lazanio, S	1
Savoja, V	1
Carbonetti, P	1
Fensore, C	1
Ferracuti, S	1
Angeletti, G	1
Tatarelli, R	1
Girardi, P	1
Howard, R	1
Schellhorn, K	1
Lumsden, J	1
Sieberer, M	1
Emrich, HM	1
Lurie, Y	1
Bentur, Y	1
Levy, Y	1
Baum, E	1
Krivoy, N	1
Tyrer, SP	1
Brittlebank, AD	1
Kröber, HL	1
Sauer, H	1
Richter, P	1
Czernik, A	1
Ludwig-Mayerhofer, W	1
Schöchlin, C	1
Greil, W	1
von Zerssen, D	1
Brewerton, TD	1
Sonne, SC	1
Brady, KT	1
Morikawa, M	1
Iida, J	1
Tokuyama, A	1
Tatsuda, H	1
Matsumoto, H	1
Kishimoto, T	1
Karlov, VA	1
Andreeva, OV	1
Hellekson, C	1
Buckland, R	1
Price, T	1
Helmchen, H	1
Ortiz de Alemán, MY	1
Castañón de Martínez, V	1
Lewin, J	1
Sumners, D	1
Tyrer, S	1
Moore, PB	1
O'Connell, RA	1
Mayo, JA	1
Sciutto, MS	1
Kutcher, SP	1
Blackwood, DH	1
Cowdry, RW	5
Gardner, DL	4
Greenberg, WM	1
Rigardetto, R	1
Pereira, JL	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Carbamazepine for the Treatment of Chronic Post-Traumatic Brain Injury Irritability and Aggression: A 42-Day, Single-Site, Forced-Titration, Parallel Group, Randomized, Double-Blind, Placebo Controlled Trial[NCT00621751]		70 participants (Actual)	Interventional	2008-02-29	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Study physician's impression of change since study onset. Clinicians Global Impressions of Change (CGI) is a sensitive, standardized tool to assess psychopharmacologic treatment response completed by the study physician. The Global Improvement (GI) CGI subscale documented the clinician's impression of change. The GI uses a 7-point scale to assess beneficial and negative effects. Low GI values (1 -3) indicate improvement; higher values (4-7) represent worsening. (NCT00621751)
Timeframe: 42 days

Global Impression of Change -- Observer

Intervention	units on a scale (Mean)
Carbamazepine	3.1
Placebo	2.9

Global Impression of Change (GIC) is a 5-item Likert Scale rated participants and observer impression of change in the person with TBI. Responses range 1 = much improved to 5 = much worse. (NCT00621751)
Timeframe: 42 days

Global Impression of Change -- Participant

Intervention	units on a scale (Mean)
Carbamazepine	3.3
Placebo	3.1

Neuropsychiatric Inventory Irritability-Aggression Domains Composite Measure -- Observer

Intervention	score on a scale (Mean)
Carbamazepine	3.1
Placebo	3.1

Neuropsychiatry Inventory-Irritability (NPI-I) & Aggression domains (NPI-A): NPI is a 40-item assessment of 12 behavioral domains (NPI-I & NPI-A domains used in this study). The most problematic aspect of each domain is graded for severity (1=mild, to 3=severe) and frequency (1-4 with 4 representing highest frequency); the domain scores (0-12) are the product of severity and frequency. To best reflect treatment target intent and meet parametric statistical method criteria, the primary outcome was a composite measure of observer-rated NPI-I & -A domains transformed to a Rasch logit scale running from 0 (best) to 100 (worse) units (i.e., observer-rated NPI-I/A Rasch construct scores). Mean day-42 observer-rated NPI-I/A Rasch construct scores were compared between placebo vs. carbamazepine using ANCOVA with baseline score as covariate. (NCT00621751)
Timeframe: 42 days

Neuropsychiatric Inventory Irritability-Aggression Domains Composite Measure Completed by Participant [Time Frame: 42 Days]

Intervention	score on a scale (Least Squares Mean)
Carbamazepine	37.7
Placebo	36.7

Neuropsychiatry Inventory-Irritability (NPI-I) & Aggression domains (NPI-A): NPI is a 40-item assessment of 12 behavioral domains (NPI-I & NPI-A domains used in this study). The most problematic aspect of each domain is graded for severity (1=mild, to 3=severe) and frequency (1-4 with 4 representing highest frequency); the domain scores (0-12) are the product of severity and frequency. To best reflect treatment target intent and meet parametric statistical method criteria, a composite measure of participant-rated NPI-I & -A domains transformed to a Rasch logit scale running from 0 (best) to 100 (worse) units (i.e., participant-rated NPI-I/A Rasch construct scores). Mean day-42 participant-rated NPI-I/A Rasch construct scores were compared between placebo vs. CBZ using ANCOVA with baseline score as covariate. (NCT00621751)
Timeframe: Day 42

Proportion of Participants With Minimal Clinically Important Difference -- Observer Rating

Intervention	score on a scale (Least Squares Mean)
Carbamazepine	37.5
Placebo	36.4

Proportion of participants with Minimal Clinically Important Difference (MCID) on Neuropsychiatric Inventory Irritability-Aggression Composite Measure completed by Observer. Specifically, the proportion of participants that experienced a decrease of > 1 (MCID) in the NPI-I/A Rasch construct score (i.e., participants that are considered to have meaningful reduction in irritability/aggression) from baseline to day-42 between the groups using a chi-square test. MCID was defined as 0.5 times the standard deviation of baseline scores. (NCT00621751)
Timeframe: 42-day

Proportion of Participants With Minimal Clinically Important Difference (MCID) -- Participant

Intervention	Participants (Count of Participants)
Carbamazepine	20
Placebo	26

Proportion of participants with Minimal Clinically Important Difference (MCID) on Neuropsychiatric Inventory Irritability-Aggression Composite Measure completed by Participant. Specifically, the proportion of participants that experienced a decrease of > 1 (MCID) in the NPI-I/A Rasch construct score (i.e., participants that are considered to have meaningful reduction in irritability/aggression) from baseline to day-42 between the groups using a chi-square test. MCID was defined as 0.5 times the standard deviation of baseline scores. (NCT00621751)
Timeframe: Day-42

Article	Year
[Empirical evidence for the use of anticonvulsants in personality disorders]. Fortschritte der Neurologie-Psychiatrie, 2009, Volume: 77, Issue:3 Topics: Amines; Anticonvulsants; Borderline Personality Disorder; Carbamazepine; Cyclohexanecarboxylic Acids	2009
The phenomenology of psychosis associated with complex partial seizure disorder. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 1997, Volume: 9, Issue:1 Topics: Adolescent; Adult; Anticonvulsants; Antipsychotic Agents; Carbamazepine; Clinical Trials as Topic; C	1997
Pharmacotherapy of the borderline patient: a critical review and clinical guidelines. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 1989, Volume: 34, Issue:4 Topics: Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Borderline Person	1989
Psychopharmacology of borderline personality disorder: a review. The Journal of clinical psychiatry, 1987, Volume: 48 Suppl Topics: Antipsychotic Agents; Borderline Personality Disorder; Carbamazepine; Humans; Monoamine Oxidase Inhi	1987
Suicidal and parasuicidal behavior in borderline personality disorder. The Psychiatric clinics of North America, 1985, Volume: 8, Issue:2 Topics: Adolescent; Adult; Alprazolam; Benzodiazepines; Borderline Personality Disorder; Carbamazepine; Diss	1985

Article	Year
Personality differences between patients with major depression and bipolar disorder--the impact of minor symptoms on self-ratings of personality. Journal of affective disorders, 1997, Volume: 42, Issue:2-3 Topics: Adult; Aged; Amitriptyline; Bipolar Disorder; Carbamazepine; Defense Mechanisms; Depressive Disorder	1997
Diagnosis of personality disorders in cocaine-dependent individuals. The American journal on addictions, 1998,Winter, Volume: 7, Issue:1 Topics: Adult; Ambulatory Care; Analgesics, Non-Narcotic; Carbamazepine; Cocaine-Related Disorders; Crack Co	1998
Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Archives of general psychiatry, 1988, Volume: 45, Issue:2 Topics: Adult; Alprazolam; Ambulatory Care; Borderline Personality Disorder; Carbamazepine; Clinical Trials	1988
Positive effects of carbamazepine on behavioral dyscontrol in borderline personality disorder. The American journal of psychiatry, 1986, Volume: 143, Issue:4 Topics: Adult; Ambulatory Care; Anger; Borderline Personality Disorder; Carbamazepine; Clinical Trials as To	1986
Development of melancholia during carbamazepine treatment in borderline personality disorder. Journal of clinical psychopharmacology, 1986, Volume: 6, Issue:4 Topics: Adult; Borderline Personality Disorder; Carbamazepine; Clinical Trials as Topic; Depressive Disorder	1986
Sedative or antimanic effects of carbamazepine and treatment of behavioral dyscontrol. The American journal of psychiatry, 1986, Volume: 143, Issue:11 Topics: Adult; Bipolar Disorder; Borderline Personality Disorder; Carbamazepine; Clinical Trials as Topic; F	1986

Article	Year
Epilepsy and brain injury: a case report of a dramatic neuropsychiatric vicious circle. Brain injury, 2013, Volume: 27, Issue:7-8 Topics: Accidents, Traffic; Aggression; Amines; Anterior Temporal Lobectomy; Anticonvulsants; Brain Injuries	2013
A biofeedback intervention to control impulsiveness in a severely personality disordered forensic patient. Personality and mental health, 2013, Volume: 7, Issue:2 Topics: Adult; Antimanic Agents; Attention; Biofeedback, Psychology; Carbamazepine; Cerebral Cortex; Conting	2013
Limited efficacy of gastrointestinal decontamination in severe slow-release carbamazepine overdose. The Annals of pharmacotherapy, 2007, Volume: 41, Issue:9 Topics: Adult; Antidotes; Antimanic Agents; Carbamazepine; Charcoal; Decontamination; Drug Overdose; Humans;	2007
Misdiagnosis of bipolar affective disorder as personality disorder. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 1993, Volume: 38, Issue:9 Topics: Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Bipolar Disorder; Carbamazepine; Combined Mo	1993
[Bipolar patients in remission: personality disorders and changes in personality]. Der Nervenarzt, 1993, Volume: 64, Issue:5 Topics: Adult; Bipolar Disorder; Carbamazepine; Cyclothymic Disorder; Depressive Disorder; Female; Hospitali	1993
[Successful treatment using low-dose carbamazepine for a patient of personality change after mild diffuse brain injury]. Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology, 2000, Volume: 20, Issue:4 Topics: Accidents, Traffic; Adult; Carbamazepine; Head Injuries, Closed; Humans; Male; Personality Disorders	2000
[Dynamics of the personality profile and cognitive functions in finlepsin treatment of partial epilepsy]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2001, Volume: 101, Issue:6 Topics: Adolescent; Adult; Anticonvulsants; Brain; Carbamazepine; Child; Cognition Disorders; Delayed-Action	2001
Organic personality disturbance: a case of apparent atypical cyclic affective disorder. The American journal of psychiatry, 1979, Volume: 136, Issue:6 Topics: Adult; Bipolar Disorder; Carbamazepine; Electroencephalography; Epilepsy, Temporal Lobe; Female; Hum	1979
[Psychiatric prognosis in epilepsies]. Schweizer Archiv fur Neurologie, Neurochirurgie und Psychiatrie = Archives suisses de neurologie, neurochirurgie et de psychiatrie, 1979, Volume: 124, Issue:1 Topics: Affective Symptoms; Carbamazepine; Chronic Disease; Epilepsy; Humans; Intellectual Disability; Neuro	1979
[Evaluation of different treatment in minimal brain damage]. Neurologia, neurocirugia, psiquiatria, 1977, Volume: 18, Issue:1 Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Carbamazepine; Child; Child, Preschool; E	1977
Successful treatment of episodic dyscontrol with carbamazepine. The British journal of psychiatry : the journal of mental science, 1992, Volume: 161 Topics: Adolescent; Aggression; Brain Damage, Chronic; Carbamazepine; Dose-Response Relationship, Drug; Head	1992
Mentally handicapped epileptic patients: psychiatric illness and personality disorder. The British journal of psychiatry : the journal of mental science, 1992, Volume: 160 Topics: Carbamazepine; Disabled Persons; Epilepsy; Female; Humans; Male; Mental Disorders; Personality Disor	1992
PDQ-R personality disorders in bipolar patients. Journal of affective disorders, 1991, Volume: 23, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Bipolar Disorder; Carbamazepine; Drug Therapy	1991
[Clinical experience with the psychopharmacological treatment with carbamazepine syrup in child behavior disorders]. Minerva pediatrica, 1974, Dec-29, Volume: 26, Issue:40 Topics: Adolescent; Affective Symptoms; Carbamazepine; Child; Child Behavior Disorders; Child, Preschool; Do	1974
[Personal experience with Tegretol in nonconvulsive behavior disorders in children]. Hospital (Rio de Janeiro, Brazil), 1969, Volume: 75, Issue:2 Topics: Adolescent; Carbamazepine; Child; Child, Preschool; Dibenzazepines; Electroencephalography; Female;	1969

carbamazepine and As If Personality